

# UCSF The Medical Management of HIV/AIDS, Hepatitis, and COVID

## 2022

A LIVE STREAM EVENT

**COURSE CHAIRS**

**Diane V. Havlir, MD**

**Meg D. Newman, MD**

**Annie Luetkemeyer, MD**

Thursday - Saturday

**December 8-10, 2022**

Presented by HIV, ID, and Global Medicine Division  
Zuckerberg San Francisco General Hospital and Trauma Center  
Department of Medicine, University of California, San Francisco



HIV, ID and Global Medicine Division  
Zuckerberg San Francisco General Hospital and Trauma Center  
Department of Medicine  
University of California, San Francisco, School of Medicine  
presents

# The Medical Management of HIV/AIDS, Hepatitis, and COVID-19

December 8-10, 2022  
Live Stream Conference

Course Chairs  
Diane V. Havlir, MD  
Meg D. Newman, MD  
Annie Luetkemeyer, MD

University of California, San Francisco



University of California, San Francisco School of Medicine

# Acknowledgement of Commercial Support

This CME activity was supported in part by educational grants from the following:

Gilead Sciences  
Janssen Therapeutics  
ViiV Healthcare

# **Exhibitors**

Gilead Sciences  
Janssen Therapeutics



University of California, San Francisco School of Medicine Presents

## **The Medical Management of HIV/AIDS and COVID-19**

This course provides the active, intermediate-to-advanced clinician with a comprehensive review of the science of HIV, Hepatitis, and COVID, as well as an update on the application of HIV, Hepatitis, and COVID therapies. For ambitious new clinicians who want a challenge, we still offer our New Clinicians Track (NCT). This track provides five additional lectures that cover antiretroviral therapy (ART) 101, basic HIV pharmacology, ART resistance, IRIS, and opportunistic infections. All course lecturers are leading clinicians and teachers who are dedicated to teaching in their areas of expertise.

The COVID pandemic has further amplified existing health disparities as well as the vulnerability of our patients, making the need for up-to-date information about HIV/AIDS, Hepatitis, and COVID essential for providing high quality care. Current treatment options for acute COVID and understanding the science and management of Long COVID will be addressed.

All lectures will be case-based with at least 2-4 ARS questions per session. Question and answer time as well as faculty panels are weaved into each conference day. The panels are designed with ARS questions so that you can privately test your individual knowledge against the experts throughout the conference. Questions that arise in the chat will be answered throughout each day by our faculty.

This symposium is offered by the HIV, ID and Global Medicine Division, Zuckerberg San Francisco General Hospital and Trauma Center, Department of Medicine, University of California, San Francisco, and the School of Medicine.

### **EDUCATIONAL OBJECTIVES**

An attendee completing this course will have improved skills and strategies to:

- Diagnose, treat, and prevent important conditions in HIV medicine and HIV medicine subspecialties, for improved patient outcomes;
- Apply in practice the latest treatment guidelines and recommendations for the prevention of HIV transmission and the appropriate use of PrEP;
- Apply new recommendations for initiating and timely switching of antiretroviral combinations in appropriate patients;
- Identify the new developments and apply treatment recommendations in HIV related dermatologic disease as well as reproductive medicine and addiction medicine;
- Apply new recommendations for the treatment of HBV, cirrhosis, NASH and NAFLD.
- Align practice patterns more with current evidence and guidelines for treating STI's, and HIV.
- Apply in practice the latest treatment guidelines and recommendations for the prevention of COVID transmission
- Apply new recommendations for appropriate treatment of acute COVID-19 and Long COVID

## ACCREDITATION

The University of California, San Francisco School of Medicine (UCSF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



UCSF designates this educational activity for a maximum of **21.25** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity meets the requirements under California Assembly Bill 1195, continuing education and cultural and linguistic competency.

### **Geriatric Medicine:**

The approved credits shown above include **4.00** Geriatric Credits toward meeting the requirement under California Assembly Bill 1820, Geriatric Medicine.

### **Pain Management and End-of-Life Care:**

The approved credits shown above include a maximum of **1.25** credits toward meeting the requirement under California Assembly Bill 487, Pain Management and End-of-Life Care.

### **ABIM Maintenance of Certification Points:**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **Nurses**

For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credit*™ issued by organizations accredited by the ACCME.

### **Physician Assistants**

AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME.

### **Pharmacists**

The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for *AMA PRA Category 1 Credit*™.

### **Family Physicians**

The AAFP has reviewed The Medical Management of HIV/AIDS, Hepatitis, and COVID and deemed it acceptable for up to 20.50 Live AAFP Prescribed credits. Term of Approval is from 12/08/2022 to 12/10/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# GENERAL INFORMATION

## ATTENDANCE VERIFICATION

---

Your attendance verification will be tracked when you log into the Zoom for the live stream course.

## SPEAKER SURVEY

---

On Thursday, December 8<sup>th</sup> you will receive an email from [Sean.Kirklen@ucsf.edu](mailto:Sean.Kirklen@ucsf.edu) through the Qualtrics system with a personalized link to access the Speaker Survey. Please make sure that you add this email to your safe senders list. If you did not receive the link, please use the chat feature to let the course staff know and they can resend. The Speaker Survey should be completed in real time during the course and is separate from the Evaluation/CME Certificate.

## EVALUATIONS / CREDITS / MOC

---

At the conclusion of the meeting, you will receive an email from [Sean.Kirklen@ucsf.edu](mailto:Sean.Kirklen@ucsf.edu) through the Qualtrics system with a link to complete your online **Course Evaluation/ Electronic CME Certificate**. Please make sure that you add this email to your safe senders list. The Qualtrics system will send you reminders to complete your CME Certificate Claiming until you complete it.

Upon completing the Electronic CME Certificate, your CME certificate will be automatically generated on your screen for you to print or save as a PDF.

The link will be available for 30 days after the last day of the course. However, after that date the link will expire and you will no longer be able to claim your credits online. You must then contact the Office of CME at [RegEmail@ocme.ucsf.edu](mailto:RegEmail@ocme.ucsf.edu) to receive your certificate and a \$15 administrative fee may be applied.

## EXHIBITS

---

Please visit our virtual exhibit hall to find out more information about our exhibitors and “meet” with them during lunch hour and breaks.

<https://hivaidscme.ucsf.edu/2021-virtual-exhibit-hall>

## FINAL PRESENTATIONS

---

A link to PDF versions of the final presentations will be sent via e-mail approximately 2 weeks post course. Only presentations that have been authorized for inclusion by the presenter will be included.

We will be recording the lectures and they will be made available 1-2 weeks after the course concludes.

**IMPORTANT:** You will receive access to the recorded material only after you have claimed credit for attending the live course format (live streaming via Zoom Meeting). Credit can only be claimed for attendance during the live stream.

## **Federal and State Law Regarding Linguistic Access and Services for Limited English Proficient Persons**

### I. Purpose.

This document is intended to satisfy the requirements set forth in California Business and Professions code 2190.1. California law requires physicians to obtain training in cultural and linguistic competency as part of their continuing medical education programs. This document and the attachments are intended to provide physicians with an overview of federal and state laws regarding linguistic access and services for limited English proficient (“LEP”) persons. Other federal and state laws not reviewed below also may govern the manner in which physicians and healthcare providers render services for disabled, hearing impaired or other protected categories

### II. Federal Law – Federal Civil Rights Act of 1964, Executive Order 13166, August 11, 2000, and Department of Health and Human Services (“HHS”) Regulations and LEP Guidance.

The Federal Civil Rights Act of 1964, as amended, and HHS regulations require recipients of federal financial assistance (“Recipients”) to take reasonable steps to ensure that LEP persons have meaningful access to federally funded programs and services. Failure to provide LEP individuals with access to federally funded programs and services may constitute national origin discrimination, which may be remedied by federal agency enforcement action. Recipients may include physicians, hospitals, universities and academic medical centers who receive grants, training, equipment, surplus property and other assistance from the federal government.

HHS recently issued revised guidance documents for Recipients to ensure that they understand their obligations to provide language assistance services to LEP persons. A copy of HHS’s summary document entitled “Guidance for Federal Financial Assistance Recipients Regarding Title VI and the Prohibition Against National Origin Discrimination Affecting Limited English Proficient Persons – Summary” is available at HHS’s website at: <http://www.hhs.gov/ocr/lep/>.

As noted above, Recipients generally must provide meaningful access to their programs and services for LEP persons. The rule, however, is a flexible one and HHS recognizes that “reasonable steps” may differ depending on the Recipient’s size and scope of services. HHS advised that Recipients, in designing an LEP program, should conduct an individualized assessment balancing four factors, including: (i) the number or proportion of LEP persons eligible to be served or likely to be encountered by the Recipient; (ii) the frequency with which LEP individuals come into contact with the Recipient’s program; (iii) the nature and importance of the program, activity or service provided by the Recipient to its beneficiaries; and (iv) the resources available to the Recipient and the costs of interpreting and translation services.

Based on the Recipient’s analysis, the Recipient should then design an LEP plan based on five recommended steps, including: (i) identifying LEP individuals who may need assistance; (ii) identifying language assistance measures; (iii) training staff; (iv) providing notice to LEP persons; and (v) monitoring and updating the LEP plan.

A Recipient’s LEP plan likely will include translating vital documents and providing either on-site interpreters or telephone interpreter services, or using shared interpreting services with other Recipients. Recipients may take other reasonable steps depending on the emergent or non-emergent needs of the LEP individual, such as hiring bilingual staff who are competent in the skills required for medical translation, hiring staff interpreters, or contracting with outside public or private agencies that provide interpreter services. HHS’s guidance provides detailed examples of the mix of services that a Recipient should consider and implement. HHS’s guidance also establishes a “safe harbor” that Recipients may elect to follow when determining whether vital documents must be translated into other languages. Compliance with the safe harbor will be strong evidence that the Recipient has satisfied its written translation obligations.

In addition to reviewing HHS guidance documents, Recipients may contact HHS’s Office for Civil Rights for technical assistance in establishing a reasonable LEP plan.



III. California Law – Dymally-Alatorre Bilingual Services Act.

The California legislature enacted the California's Dymally-Alatorre Bilingual Services Act (Govt. Code 7290 *et seq.*) in order to ensure that California residents would appropriately receive services from public agencies regardless of the person's English language skills. California Government Code section 7291 recites this legislative intent as follows:

"The Legislature hereby finds and declares that the effective maintenance and development of a free and democratic society depends on the right and ability of its citizens and residents to communicate with their government and the right and ability of the government to communicate with them.

The Legislature further finds and declares that substantial numbers of persons who live, work and pay taxes in this state are unable, either because they do not speak or write English at all, or because their primary language is other than English, effectively to communicate with their government. The Legislature further finds and declares that state and local agency employees frequently are unable to communicate with persons requiring their services because of this language barrier. As a consequence, substantial numbers of persons presently are being denied rights and benefits to which they would otherwise be entitled.

It is the intention of the Legislature in enacting this chapter to provide for effective communication between all levels of government in this state and the people of this state who are precluded from utilizing public services because of language barriers."

The Act generally requires state and local public agencies to provide interpreter and written document translation services in a manner that will ensure that LEP individuals have access to important government services. Agencies may employ bilingual staff, and translate documents into additional languages representing the clientele served by the agency. Public agencies also must conduct a needs assessment survey every two years documenting the items listed in Government Code section 7299.4, and develop an implementation plan every year that documents compliance with the Act. You may access a copy of this law at the following url: <http://www.spb.ca.gov/bilingual/dymallyact.htm>

# Faculty List

## Course Chairs

### **Diane V. Havlir, MD**

Professor of Medicine, Director AIDS Research Institute, Chief, HIV, ID and Global Medicine  
Division of HIV, Infectious Diseases, and Global Medicine Division  
Zuckerberg San Francisco General Hospital and Trauma Center

### **Meg D. Newman, MD**

UCSF Senate Emeritus  
Division of HIV, Infectious Diseases, and Global Medicine Division  
Zuckerberg San Francisco General Hospital and Trauma Center

### **Annie Luetkemeyer, MD**

Professor of Medicine  
Division of HIV, Infectious Diseases, and Global Medicine Division  
Zuckerberg San Francisco General Hospital and Trauma Center

## Course Faculty (UCSF Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center unless indicated)

### **Soraya Azari, MD**

Associate Professor of Medicine, Division of General Internal Medicine

### **Jennifer Babik, MD, PhD**

Professor of Medicine

### **Oliver M. Bacon, MD, MPH**

Associate Clinical Professor  
Senior Physician, San Francisco City Clinic, San Francisco Department of Public Health

### **Debika Bhattacharya, MD**

Associate Professor of Medicine, UCLA

### **Derek Blechinger, MD**

Senior Physician; Core Faculty, Kaiser Permanente Northern California HIV Fellowship

### **Gabriel Chamie, MD**

Associate Professor of Medicine

### **Franco Chevalier, MD**

Infectious Diseases Fellow

### **Susa Coffey, MD**

Professor of Medicine

### **Phillip Coffin, MD**

Director of Substance Use Research, San Francisco Department of Public Health

### **Deborah Cohan, MD, MPH**

Professor of Obstetrics, Gynecology and Reproductive Sciences;  
Medical Director, HIVE

### **Stephanie Cohen, MD**

Director, HIV/STI Prevention

**Course Faculty** (UCSF Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center unless indicated)

**Kathleen Corey, MD**

Associate Professor, Harvard Medical School  
Director, MGH NAFLD Program

**Steven Deeks, MD**

Professor of Medicine

**Matthew Durstenfeld, MD**

Assistant Professor of Medicine, Division of Cardiology

**Michelle Estrella, MD**

Professor of Medicine  
Chief, Renal Section, SF VA Health Care System  
Executive Director, Kidney Health Research Collaborative

**Charles Flexner, MD**

Professor of Medicine, Pharmacology, and International Health  
Johns Hopkins University, Baltimore, MD

**Monica Gandhi, MD, MPH**

Professor of Medicine

**Katherine Grieco, DO**

Faculty, Rushford Addiction Medicine Fellowship  
Hartford Healthcare, Hartford, CT

**C. Bradley Hare, MD**

Chief, Infectious Diseases and HIV, Kaiser-Permanente, San Francisco

**Matthew Hickey, MD**

Assistant Professor of Medicine

**Priscilla Hsue, MD**

Maurice Eliaser Jr., MD Distinguished Professor of Medicine  
Chief of Cardiology UCSF at ZSFG

**Elizabeth Imbert, MD, MPH**

Associate Professor of Medicine

**Vivek Jain, MD, MAS**

Professor of Medicine

**Andrew Kerkhoff, MD, PhD**

Assistant Professor of Medicine

**Harry Lampiris, MD**

Professor of Clinical Medicine  
Chief, Infectious Disease Section San Francisco VA Medical Center

**Kieron Leslie, MBBS, MD**

Professor of Clinical Dermatology

**Course Faculty** (UCSF Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center unless indicated)

**Albert Liu, MD**

Professor of Medicine  
Clinical Research Director, Bridge HIV

**Carina Marquez, MD, MPH**

Associate Professor of Medicine

**Nicky Mehtani, MD**

Post-Doctoral Fellow, UCSF Department of Psychiatry

**Anthony Muiru, MD**

Assistant Professor of Medicine, Division of Nephrology

**Elizabeth Murphy, MD**

Professor of Clinical Medicine  
Deborah Cowan Endowed Professorship in Endocrinology  
Chief, Division of Endocrinology, SFGH

**Joel Palefsky, MD, FRCP (C)**

Professor of Medicine  
Director UCSF Anal Neoplasia Clinic Research and Education Center

**Michael Peluso, MD**

Assistant Professor of Medicine

**Jennifer Price, MD, PhD**

Associate Professor of Medicine  
Director, UCSF Viral Hepatitis Center

**Theodore Ruel, MD**

Chief, Division of Pediatric Infectious Disease and Global Health

**Parya Saberi, PharmD, MAS**

Associate Professor of Medicine  
UCSF Division of Prevention Science

**Hyman Scott, MD**

Assistant Professor of Medicine  
Medical Director, Bridge HIV, San Francisco Department of Public Health

**Mark Smith, MD**

Clinical Professor of Medicine

**Matthew Spinelli, MD, MAS**

Assistant Professor of Medicine

**John Szumowski, MD**

Assistant Clinical Professor

**Lisa G. Winston, MD**

Professor, UCSF;  
Chief of Staff and Hospital Epidemiologist, Zuckerberg San Francisco General Hospital

## Disclosures

The following individuals have disclosed they have no financial interest/arrangement or affiliation with any commercial interests who provide products or services relating to their presentation(s) in this continuing medical education activity:

Diane V. Havlir, MD	Elizabeth Imbert, MD, MPH
Meg D. Newman, MD, FACP	Andrew Kerkhoff, MD, PhD
Jennifer Babik, MD, PhD	Harry Lampiris, MD
Oliver M. L. Bacon, MD, MPH	Kieron Leslie, MBBS, MD
Derek Blechinger, MD	Nicky Mehtani, MD
Susan Buchbinder, MD	Elizabeth Murphy, MD
Gabriel Chamie, MD	Michael Peluso
Felicia Chow, MD	Sarah Puryear, MD, PhD
Susa Coffey, MD	Parya Saberi, PharmD, MAS
Deborah Cohan, MD, MPH	Luis Alberto Rubio, MD, MHS
Stephanie Cohen, MD	Theodore Ruel, MD
Monica Gandhi, MD, MPH	Hyman Scott, MD
Katherine Grieco, DO, FASAM	John Szumowski, MD
Matthew Hickey, MD	Lisa G. Winston, MD
Laurence Huang, MD	

The following individuals have disclosed having a financial interest/arrangement or affiliation during the past twelve months with a commercial interest who provides products or services relating to their presentation(s) in this continuing medical education activity. All conflicts of interest have been resolved in accordance with the ACCME *Standards for Commercial Support*:

Annie Luetkemeyer, MD	AstraZeneca Gilead GSK Mayne Pharma Hologic Cepheid	Grant/Research Support Grant/Research Support Grant/Research Support Grant/Research Support Grant/Research Support Grant/Research Support
Debika Bhattacharya, MD	Gilead	Grant/Research Support
Kathleen E. Corey, MD	AstraZeneca Theratechnologies BMS	Advisor/Reviewer Advisor/Reviewer Grant/Research Support
Steven Deeks, MD	GSK Immunocore Enochian Biosciences Tendel	Advisor/Reviewer Advisor/Reviewer Advisor/Reviewer Board Member
Michelle Estrella, MD	AstraZeneca Bayer Boehringer-Ingelheim	Consultant Grant/Research Support Consultant

This UCSF CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

The following individuals have disclosed having a financial interest/arrangement or affiliation during the past twelve months with a commercial interest who provides products or services relating to their presentation(s) in this continuing medical education activity. All conflicts of interest have been resolved in accordance with the ACCME *Standards for Commercial Support*:

Charles Flexner, MD	Gilead Janssen Merck ViiV Healthcare Navigen	Consultant/ Honorarium Recipient Consultant Consultant Consultant Board Member/ Stock Shareholder (excluding mutual funds)
C. Bradley Hare, MD	Gilead	Grant/Research Support
Priscilla Hsue, MD	Gilead Merck Novartis	Honorarium Honorarium Grant/Research Support
Vivek Jain, MD, MAS	Shionogi, Inc.	Advisor/Reviewer
Albert Liu, MD	ViiV Healthcare Gilead Sciences	Grant/Research Support Grant/Research Support
Joel Palefsky, MD	Merck Vir Biotechnologies Virion Therapeutics  Roche Diagnostics Antiva Biosciences	Consultant/ Honorarium Recipient Consultant/ Honorarium Recipient Consultant/ Stock Shareholder (excluding mutual funds) Consultant/ Honorarium Recipient Consultant/ Honorarium Recipient
Michael Peluso, MD	Gilead AstraZeneca American Gene Technologies	Consultant Consultant Honorarium Recipient
Jennifer Price, MD, PhD	Merck Gilead AbbVie	Grant/Research Support Grant/Research Support Grant/Research Support
Mark Smith, MD	Phreesia Jazz Pharmaceuticals Teladoc Health ConcertoCare Prealize	Board Member Board Member Board Member Advisor/Reviewer Board Member

This UCSF CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

This activity has been reviewed and approved by members of the UCSF CME Governing Board in accordance with UCSF CME accreditation policies. Office of CME staff, planners, reviewers, and all others in control of content have disclosed they have no relevant financial relationships.

# COURSE PROGRAM

**Thursday, December 10, 2022**

8:00	Introduction	Drs. Diane Havlir, Meg Newman, & Annie Luetkemeyer
------	--------------	--

**PLENARY SESSION I: State of HIV: 2021 Perspective**

8:10	Top Ten Issues in HIV Medicine	Dr. Diane Havlir
8:50	Modern ART: What Lies Ahead?	Dr. Charles Flexner
9:30	<b>Chronic Pain and Opioids Among People with HIV: Patients and Providers Navigating the Current Environment Together</b>	Drs. Phillip Coffin/ Soraya Azari
10:10	<i>Break</i>	

**PLENARY SESSION II: HIV Prevention**

10:40	Introductory Remarks	Dr. Mark Smith
10:50	The Leading Edge of Prevention	Dr. Albert Liu
11:20	<b>PEP, PrEP, and DoxyPEP: Cases and Controversies from the Clinic</b>	Moderator: Dr. Oliver Bacon Panelists: Drs. Stephanie Cohen Derek R. Blechinger Hyman Scott
11:50	<b>Q&amp;A</b>	
12:00 PM	<i>Break</i>	

**OPTIONAL LUNCH WORKSHOP:**

12:15 1:05	<b><sup>NCT</sup>New Clinicians' Workshop: ART101: Antiretroviral Therapy Initiation: From Guidelines to Practice</b>	Dr. Vivek Jain
---------------	---	----------------

**PLENARY SESSION III: Antiretroviral Therapy – State of the ART**

1:30	The State of the Art of ART	Dr. Monica Gandhi
2:10	<b>G Weight Gain in HIV: Cases from the Clinic</b>	Dr. Matthew Hickey
2:40	<b>Cases and Challenges with ART</b>	Moderator: Dr. Matt Spinelli Panelists: Drs. Brad Hare, Gabe Chamie, Vivek Jain
3:15	<i>Break</i>	

**PLENARY SESSION IV: Infectious Complications of HIV**

3:30	Great Cases from the Bay	Moderator: Dr. Andrew Kerkhoff Drs. Jennifer Babik, Franco Chevalier
4:15	<b>Management of Sexually Transmitted Infections: Monkeypox and More</b>	Dr. Stephanie Cohen
5:00 PM	<i>Adjourn</i>	

NCT = New Clinicians' Track

P = Pain Credit

G = Geriatric Credit

## Friday, December 11, 2022

### PLENARY SESSION V: COVID & Care of the Liver Patient

8:00	<b>G</b>	<b>COVID Vaccines</b>	Dr Carina Marquez
8:25	<b>G</b>	<b>Navigating COVID-19 Treatment Options</b>	Dr. Annie Luetkemeyer
9:00	<b>G</b>	<i>Break x 5 min</i>	
9:05		<b>The Evolving Science of Long COVID</b>	Dr. Steve Deeks
9:35	<b>G</b>	<b>Managing Long COVID: Cases from the Clinic</b>	Dr. Michael Peluso
9:50	<b>G</b>	<b>COVID Panel with Q&amp;A</b>	Drs. Marquez, Peluso, Luetkemeyer, Deeks, Ruel
10:10		<i>Break x 30 min</i>	
10:40		<b>Advances in Hepatitis B and D</b>	Dr. Debika Bhattacharya
11:05		<b>Top 10 Questions in Hepatitis and Cirrhosis Management</b>	Dr. Jennifer Price
11:25	<b>G</b>	<b>NAFLD and NASH: Cases from the Clinic</b>	Dr. Kathleen E. Corey
11:50		<b>Liver Panel with Q&amp;A</b>	Drs. Bhattacharya Corey, & Price
12:00 PM		<i>Lunch</i>	

### OPTIONAL LUNCH WORKSHOPS:

#### TRACK A

12:10– 1:00		<b>Cases from the Clinic: Optimizing Care for Vulnerable Populations</b>	Dr. Liz Imbert
----------------	--	--	----------------

#### TRACK B <sup>NCT</sup>New Clinicians' Workshop

12:10 – 1:00		<b>The Building Blocks of HIV Therapy</b>	Dr. Parya Saberi
-----------------	--	---	------------------

### PLENARY SESSION VI: Reproductive Health and Dermatology **Moderator: Meg Newman**

1:20		<b>HIV and Reproductive Health and Justice</b>	Dr. Deborah Cohan
2:00		<b>HIV Dermatology: Cases from the Clinic Including Monkeypox</b>	Dr. Kieron Leslie
2:45		<i>Break</i>	

### PLENARY SESSION VII: HPV

3:00	<b>G</b>	<b>HPV After the ANCHOR Study: Dawn of a New Era in Screening and Treatment</b>	Dr. Joel Palefsky
------	----------	---	-------------------

#### PARALLEL TRACKS (choose one)

#### <sup>NCT</sup>New Clinicians' Workshops

3:45 – 4:25		<sup>NCT</sup> <b>Introduction to ARV Drug Resistance</b>	Dr. Susa Coffey
4:30 – 5:15 PM		<sup>NCT</sup> <b>Opportunistic Infections and IRIS</b>	Dr. Andrew Kerkhoff

#### Infectious Disease Updates for HIV Clinicians

3:45 – 4:25		<b>ID Pearls for HIV Providers</b>	Dr. Lisa Winston
4:30 – 5:15		<b>A Year in Clinical Images</b>	Dr. Matthew Spinelli

NCT = New Clinicians' Track

P = Pain Credit

G = Geriatric Credit



## Saturday, December 12, 2022

### **PLENARY SESSION VIII: Optimizing Care of the HIV Patient**

8:00 AM	<b>G</b>	<b>HIV and Cardiovascular Disease for the Non-Cardiologist</b>	Dr. Priscilla Hsue/ Dr. Matt Durstenfeld
8:40		<b>Cases from the STI Clinic</b>	Dr. Oliver Bacon
9:20	<b>P</b>	<b>Substance Use Trends in the US: What Providers Need to Know</b>	Dr. Katherine Grieco
10:00		<i>Break</i>	
10:20	<b>P</b>	<b>Cases in Addiction Medicine and Pain Management</b>	Dr. Nicky Mehtani
10:50		<b>Pain Panel</b>	Drs. Mehtani, Grieco, Azari, Coffin
11:20		<b>HIV and the Kidney Update: Cases from the Clinic</b>	Dr. Michelle Estrella / Dr. Anthony Muiru
12:05		<b>Lunch</b>	

### **PLENARY SESSION IX: ART Management, and Endocrinology Updates**

1:20		<b>ART Panel: Integrating Your Knowledge: What Would You Recommend for These Patients?</b>	Moderator: Dr. Susa Coffey Panelists: Drs. John Szumowski, Harry Lampiris, Annie Luetkemeyer
2:00		<b>HIV in Children and Adolescents: Consensus and Controversies</b>	Dr. Ted Ruel
2:40		<i>Break</i>	
3:00	<b>G</b>	<b>Endocrine Update 2022</b>	Dr. Elizabeth Murphy
3:40		<b>Closing Remarks</b>	Drs. Diane Havlir, Meg Newman, and Annie Luetkemeyer
4:00 PM		<i>Adjourn</i>	

NCT = New Clinicians' Track

P = Pain Credit

G = Geriatric Credit

# **Upcoming CME Courses**

Infectious Diseases in Clinical Practice:  
Update on Inpatient and Outpatient Infectious Diseases  
Thursday, February 19 – Saturday, February 24, 2023  
Kauai, HI

The Musculoskeletal System at Work and  
Updates in Occupational and Environmental Medicine  
Thursday, March 9 – Saturday, March 11, 2023  
San Francisco, CA

16<sup>h</sup> International Conference Neonatal & Childhood Pulmonary Vascular Disease  
Thursday, March 16 – Saturday, March 18, 2023  
San Francisco, CA

Diabetes Update and Advances in Endocrinology and Metabolism  
Thursday, March 30 – Saturday, April 1, 2023  
San Francisco, CA

Primary Care Medicine: Update 2023  
Saturday, April 2 – Friday, April 7, 2023  
Honolulu, HI

**All Courses Managed by:  
UCSF Office of Continuing Medical Education  
490 Illinois Street, Floor 8, San Francisco, CA 94143  
For registration information call: 415-476-4251  
Visit the web site at [www.cme.ucsf.edu](http://www.cme.ucsf.edu)**